Werewolf Therapeutics, a Cambridge, Mass.-based oncology biotherapeutics company advancing a pipeline of transformative cancer treatments, completed a $56m Series A financing.
The round was led by MPM Capital and Longwood Fund, with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners.
Led by Daniel J. Hicklin, Ph.D. President and CEO, Werewolf Therapeutics is developing novel immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer.
The company’s PREDATOR™ protein engineering platform creates potent biologics that can be systemically delivered in an inactivated format to prevent unwanted effects on non-target tissues. In the tumor microenvironment, these molecules are selectively activated to deliver the full biological potency of cytokines and immune stimulatory antibodies for maximum therapeutic potential.
The company intends to use the funds to invest in research, talent acquisition and advancement of its platform and therapeutic programs to early clinical development. Initial areas of drug development will focus on INDUKINESTM, conditionally activated cytokines that are designed to safely and effectively deliver potent antitumor immunity.
Luke Evnin, Ph.D., co-founder and Managing Director, MPM Capital, is the co-founder and Chairman of Werewolf Therapeutics.